                         SEQUENCE LISTING

<110>  Zealand Pharma A/S
 
<120>  Composition

<130>  P122070PCT

<160>  178     

<170>  PatentIn version 3.5


<210>  1
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-1 dual agonist peptide


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa is Aib or G

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Xaa is T or S with at least one of Xaa at position 5 or 7 being a
       T

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Xaa is T or S with at least one of Xaa at position 5 or 7 being a
       T

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  Xaa is S, E or D

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Xaa is L, M, V or a residue of K, k (D-lys), R, Orn, Dap or Dab 
       in which the side chain is conjugated to a substituent

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  Xaa is A, N or S

<220>
<221>  MISC_FEATURE
<222>  (15)..(15)
<223>  Xaa is D or E

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is G, E, A or a residue of K, k (D-lys), R, Orn, Dap or Dab 
       in which the side chain is conjugated to a substituent

<220>
<221>  MISC_FEATURE
<222>  (17)..(17)
<223>  Xaa is Q, E, K, L or a residue of K, k (D-lys), R, Orn, Dap or 
       Dab in which the side chain is conjugated to a substituent

<220>
<221>  MISC_FEATURE
<222>  (19)..(19)
<223>  Xaa is A, V or S

<220>
<221>  MISC_FEATURE
<222>  (20)..(20)
<223>  Xaa is R, K or a residue of K, k (D-lys), R, Orn, Dap or Dab in 
       which the side chain is conjugated to a substituent

<220>
<221>  MISC_FEATURE
<222>  (21)..(21)
<223>  Xaa is D, L or E

<220>
<221>  MISC_FEATURE
<222>  (24)..(24)
<223>  Xaa is A, N or  S

<220>
<221>  MISC_FEATURE
<222>  (27)..(27)
<223>  Xaa is I, Q, K, H or Y

<220>
<221>  MISC_FEATURE
<222>  (28)..(28)
<223>  Xaa is Q, E, A, H, Y, L, K, R or S

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  Xaa is H, Y, K or Q

<220>
<221>  MISC_FEATURE
<222>  (33)..(33)
<223>  Xaa is D or  E

<400>  1

His Xaa Glu Gly Xaa Phe Xaa Xaa Glu Xaa Xaa Thr Ile Leu Xaa Xaa 
1               5                   10                  15      


Xaa Ala Xaa Xaa Xaa Phe Ile Xaa Trp Leu Xaa Xaa Xaa Lys Ile Thr 
            20                  25                  30          


Xaa 
    


<210>  2
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa is Aib or G

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Xaa is T or S

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Xaa is T or S

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is G or a residue of K, k (D-lys), R, Orn, Dap or Dab in 
       which the side chain is conjugated to a substituent

<220>
<221>  MISC_FEATURE
<222>  (17)..(17)
<223>  Xaa is Q, E, K, L or a residue of K, k (D-lys), R, Orn, Dap or 
       Dab in which the side chain is conjugated to a substituent

<220>
<221>  MISC_FEATURE
<222>  (21)..(21)
<223>  Xaa is D or L

<220>
<221>  MISC_FEATURE
<222>  (28)..(28)
<223>  Xaa is Q, E, A, H, Y, L, K, R or S

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  Xaa is H, Y or Q

<400>  2

His Xaa Glu Gly Xaa Phe Xaa Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Xaa Ala Ala Arg Xaa Phe Ile Ala Trp Leu Ile Xaa Xaa Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  3
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Xaa is T or S with at least one of Xaa at position 5 or 7 being 
       a T

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Xaa is T or S with at least one of Xaa at position 5 or 7 being 
       a T

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Xaa is L or a residue of K, k (D-lys), R, Orn, Dap or Dab in 
       which the side chain is conjugated to a substituent

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is G, E, A or a residue of K, k (D-lys), R, Orn, Dap or Dab 
       in which the side chain is conjugated to a substituent

<220>
<221>  MISC_FEATURE
<222>  (17)..(17)
<223>  Xaa is Q, E, K, L or a residue of K, k (D-lys), R, Orn, Dap or 
       Dab in which the side chain is conjugated to a substituent

<220>
<221>  MISC_FEATURE
<222>  (20)..(20)
<223>  Xaa is R or a residue of K, k (D-lys), R, Orn, Dap or Dab in 
       which the side chain is conjugated to a substituent

<220>
<221>  MISC_FEATURE
<222>  (21)..(21)
<223>  Xaa is D or L

<220>
<221>  MISC_FEATURE
<222>  (28)..(28)
<223>  Xaa is E, A or Q

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  Xaa is H, Y or Q

<400>  3

His Xaa Glu Gly Xaa Phe Xaa Ser Glu Xaa Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Xaa Ala Ala Xaa Xaa Phe Ile Ala Trp Leu Ile Xaa Xaa Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  4
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Xaa is T or S with at least one of Xaa at position 5 or 7 being a
       T

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Xaa is T or S with at least one of Xaa at position 5 or 7 being a
       T

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is G or a residue of K, k (D-lys), R, Orn, Dap or Dab in 
       which the side chain is conjugated to a substituent

<220>
<221>  MISC_FEATURE
<222>  (17)..(17)
<223>  Xaa is E, K, L or a residue of K, k (D-lys), R, Orn, Dap or Dab 
       in which the side chain is conjugated to a substituent

<220>
<221>  MISC_FEATURE
<222>  (21)..(21)
<223>  Xaa is D or L

<220>
<221>  MISC_FEATURE
<222>  (28)..(28)
<223>  Xaa is E or A

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  Xaa is H, Y or Q

<400>  4

His Xaa Glu Gly Xaa Phe Xaa Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Xaa Ala Ala Arg Xaa Phe Ile Ala Trp Leu Ile Xaa Xaa Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  5
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Xaa is T or S where at least one of Xaa at position 5 or 7 is a T

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Xaa is T or S where at least one of Xaa at position 5 or 7 is a T

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<220>
<221>  MISC_FEATURE
<222>  (28)..(28)
<223>  Xaa is Q, E, A, H, Y, L, K, R or S, e.g. Q, E, A, H, Y or L

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  Xaa is H, Y or Q

<400>  5

His Xaa Glu Gly Xaa Phe Xaa Ser Glu Leu Ala Thr Ile Leu Asp Xaa Gln 
1               5                   10                  15      


Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Xaa Xaa Lys Ile Thr Asp 
         20                  25                  30             



<210>  6
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  PEPTIDE
<222>  (1)..(6)
<223>  Xaa is D-lys

<220>
<221>  MISC_FEATURE
<222>  (1)..(6)

<400>  6

Xaa Xaa Xaa Xaa Xaa Xaa 
1               5       



<210>  7
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide

<400>  7

Glu Lys Glu Lys Glu Lys 
1               5       


<210>  8
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa is D-lys

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa is D-lys

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Xaa is D-lys

<400>  8

Glu Xaa Glu Xaa Glu Xaa 
1               5       


<210>  9
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide

<400>  9

Ala Lys Ala Ala Glu Lys 
1               5       


<210>  10
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide

<400>  10

Ala Lys Glu Lys Glu Lys 
1               5       


<210>  11
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide

<400>  11

Ala Thr Ile Leu Glu Lys 
1               5       


<210>  12
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  12

Glu Lys Glu Lys Glu Xaa 
1               5       


<210>  13
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa is D-lys

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa is D-lys

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  13

Glu Xaa Glu Xaa Glu Xaa 
1               5       


<210>  14
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  14

Ala Lys Ala Ala Glu Xaa 
1               5       


<210>  15
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  15

Ala Lys Glu Lys Glu Xaa 
1               5       


<210>  16
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  16

Ala Thr Ile Leu Glu Xaa 
1               5       


<210>  17
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  17

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Glu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  18
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  18

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Glu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  19
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  19

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Glu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  20
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  20

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Lys Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  21
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  21

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Lys Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  22
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  22

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Lys Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  23
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (17)..(17)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  23

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Gly 
1               5                   10                  15      


Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  24
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (17)..(17)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  24

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Gly 
1               5                   10                  15      


Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  25
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (17)..(17)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  25

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Gly 
1               5                   10                  15      


Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  26
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  26

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  27
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  27

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  28
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  28

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  29
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  29

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  30
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  30

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  31
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  31

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  32
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  32

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Glu Ala Ala Arg Leu Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  33
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  33

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  34
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  34

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  35
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  35

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  36
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  36

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  37
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  37

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  38
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  38
His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  39
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  39

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  40
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  40

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  41
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  41

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  42
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  42

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile His His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  43
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  43

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Tyr His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  44
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  44

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Leu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  45
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  45

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Lys His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  46
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  46

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Arg His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  47
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  47

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ser His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  48
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  48

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Gln Gln His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  49
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  49

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Tyr Gln His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  50
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  50

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Lys Gln His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  51
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  51

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln Gln Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  52
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  52

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln Tyr Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  53
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  53

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ser Thr Ile Leu Glu Xaa 
1               5                   10                  15      


Gln Ala Ser Arg Glu Phe Ile Ala Trp Leu Ile Ala Tyr Lys Ile Thr 
            20                  25                  30          


Glu 
    


<210>  54
<211>  39
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (34)..(38)
<223>  Xaa at positions 34-38 is D-Lys

<220>
<221>  MISC_FEATURE
<222>  (39)..(39)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  54

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Glu 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr 
            20                  25                  30          


Asp Xaa Xaa Xaa Xaa Xaa Xaa 
        35                  


<210>  55
<211>  39
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (34)..(38)
<223>  Xaa at positions 34-38 is D-Lys

<220>
<221>  MISC_FEATURE
<222>  (39)..(39)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  55

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr 
            20                  25                  30          


Asp Xaa Xaa Xaa Xaa Xaa Xaa 
        35                  


<210>  56
<211>  39
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (34)..(38)
<223>  Xaa at positions 34-38 is D-Lys

<220>
<221>  MISC_FEATURE
<222>  (39)..(39)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  56

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp Xaa Xaa Xaa Xaa Xaa Xaa 
        35                  


<210>  57
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  57

His Xaa Glu Gly Ser Phe Thr Ser Glu Xaa Ala Thr Ile Leu Asp Glu 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  58
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (17)..(17)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  58

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Glu Gly 
1               5                   10                  15      


Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  59
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (20)..(20)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  59

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu 
1               5                   10                  15      


Gln Ala Ala Xaa Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  60
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (20)..(20)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  60

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu 
1               5                   10                  15      


Gln Ala Ala Xaa Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  61
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  61

His Xaa Glu Gly Thr Phe Thr Ser Glu Xaa Ala Thr Ile Leu Asp Glu 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  62
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (17)..(17)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  62

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Ala 
1               5                   10                  15      


Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  63
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (20)..(20)
<223>  Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
       side chain is conjugated to a substituent

<400>  63

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Ala 
1               5                   10                  15      


Lys Ala Ala Xaa Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  64
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa indicates an L-lysine residue in which the side chain is 
       conjugated to the substituent Z1- or Z1Z2

<400>  64

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Glu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  65
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa indicates an L-lysine residue in which the side chain is 
       conjugated to the substituent Z1- or Z1Z2

<400>  65

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Glu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 



<210>  66
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa indicates an L-lysine residue in which the side chain is 
       conjugated to the substituent Z1- or Z1Z2

<400>  66

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Glu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  67
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa indicates an L-lysine residue in which the side chain is 
       conjugated to the substituent Z1- or Z1Z2

<400>  67

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Lys Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  68
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa indicates an L-lysine residue in which the side chain is 
       conjugated to the substituent Z1- or Z1Z2

<400>  68

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Lys Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  69
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa indicates an L-lysine residue in which the side chain is 
       conjugated to the substituent Z1- or Z1Z2

<400>  69

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Lys Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  70
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (17)..(17)
<223>  Xaa indicates an L-lysine residue in which the side chain is 
       conjugated to the substituent Z1- or Z1Z2

<400>  70

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Gly 
1               5                   10                  15      


Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  71
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (17)..(17)
<223>  Xaa indicates an L-lysine residue in which the side chain is 
       conjugated to the substituent Z1- or Z1Z2

<400>  71

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Gly 
1               5                   10                  15      


Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  72
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (17)..(17)
<223>  Xaa indicates an L-lysine residue in which the side chain is 
       conjugated to the substituent Z1- or Z1Z2

<400>  72
His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Gly 
1               5                   10                  15      


Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  73
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa indicates an L-lysine residue in which the side chain is 
       conjugated to the substituent Z1- or Z1Z2

<400>  73

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  74
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa indicates an L-lysine residue in which the side chain is 
       conjugated to the substituent Z1- or Z1Z2

<400>  74

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  75
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa indicates an L-lysine residue in which the side chain is 
       conjugated to the substituent Z1- or Z1Z2

<400>  75

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  76
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa indicates an L-lysine residue in which the side chain is 
       conjugated to the substituent Z1- or Z1Z2

<400>  76

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  77
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa indicates an L-lysine residue in which the side chain is 
       conjugated to the substituent Z1- or Z1Z2

<400>  77

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  78
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa indicates an L-lysine residue in which the side chain is 
       conjugated to the substituent Z1- or Z1Z2

<400>  78

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  79
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa indicates an L-lysine residue in which the side chain is 
       conjugated to the substituent Z1- or Z1Z2

<400>  79

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Glu Ala Ala Arg Leu Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  80
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa indicates an L-lysine residue in which the side chain is 
       conjugated to the substituent Z1- or Z1Z2

<400>  80

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  81
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa indicates an L-lysine residue in which the side chain is 
       conjugated to the substituent Z1- or Z1Z2

<400>  81

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  82
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa indicates an L-lysine residue in which the side chain is 
       conjugated to the substituent Z1- or Z1Z2

<400>  82

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  83
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa indicates an L-lysine residue in which the side chain is 
       conjugated to the substituent Z1- or Z1Z2

<400>  83

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  84
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa indicates an L-lysine residue in which the side chain is 
       conjugated to the substituent Z1- or Z1Z2

<400>  84

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  85
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa indicates an L-lysine residue respectively in which the side 
       chain is conjugated to the substituent Z1- or Z1Z2

<400>  85

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  86
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa indicates an L-lysine residue in which the side chain is 
       conjugated to the substituent Z1- or Z1Z2

<400>  86

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  87
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa indicates an L-lysine residue in which the side chain is 
       conjugated to the substituent Z1- or Z1Z2

<400>  87

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  88
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa indicates an L-lysine residue in which the side chain is 
       conjugated to the substituent Z1- or Z1Z2

<400>  88

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  89
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa indicates an L-lysine residue in which the side chain is 
       conjugated to the substituent Z1- or Z1Z2

<400>  89

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile His His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  90
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa indicates an L-lysine residue in which the side chain is 
       conjugated to the substituent Z1- or Z1Z2

<400>  90

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Tyr His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  91
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa indicates an L-lysine residue in which the side chain is 
       conjugated to the substituent Z1- or Z1Z2

<400>  91

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Leu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  92
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa indicates an L-lysine residue in which the side chain is 
       conjugated to the substituent Z1- or Z1Z2

<400>  92

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Lys His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  93
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa indicates an L-lysine residue in which the side chain is 
       conjugated to the substituent Z1- or Z1Z2

<400>  93

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Arg His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  94
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa indicates an L-lysine residue in which the side chain is 
       conjugated to the substituent Z1- or Z1Z2

<400>  94

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ser His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  95
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa indicates an L-lysine residue in which the side chain is 
       conjugated to the substituent Z1- or Z1Z2

<400>  95

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Gln Gln His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  96
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa indicates an L-lysine residue in which the side chain is 
       conjugated to the substituent Z1- or Z1Z2

<400>  96

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Tyr Gln His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  97
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa indicates an L-lysine residue in which the side chain is 
       conjugated to the substituent Z1- or Z1Z2

<400>  97

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Lys Gln His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  98
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa indicates an L-lysine residue in which the side chain is 
       conjugated to the substituent Z1- or Z1Z2

<400>  98

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln Gln Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  99
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa indicates an L-lysine residue in which the side chain is 
       conjugated to the substituent Z1- or Z1Z2

<400>  99

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln Tyr Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  100
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa indicates an L-lysine residue in which the side chain is 
       conjugated to the substituent Z1- or Z1Z2

<400>  100

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ser Thr Ile Leu Glu Xaa 
1               5                   10                  15      


Gln Ala Ser Arg Glu Phe Ile Ala Trp Leu Ile Ala Tyr Lys Ile Thr 
            20                  25                  30          


Glu 
    


<210>  101
<211>  39
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (34)..(38)
<223>  Xaa at positions 34-38 is D-Lys

<220>
<221>  MISC_FEATURE
<222>  (39)..(39)
<223>  Xaa indicates a D-lysine residue in which the side chain is 
       conjugated to the substituent Z1- or Z1Z2

<400>  101

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Glu 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr 
            20                  25                  30          


Asp Xaa Xaa Xaa Xaa Xaa Xaa 
        35                  


<210>  102
<211>  39
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (34)..(38)
<223>  Xaa at positions 34-38 is D-Lys

<220>
<221>  MISC_FEATURE
<222>  (39)..(39)
<223>  Xaa indicates a D-lysine residue in which the side chain is 
       conjugated to the substituent Z1- or Z1Z2

<400>  102

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr 
            20                  25                  30          


Asp Xaa Xaa Xaa Xaa Xaa Xaa 
        35                  


<210>  103
<211>  39
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (34)..(38)
<223>  Xaa at positions 34-38 is D-Lys

<220>
<221>  MISC_FEATURE
<222>  (39)..(39)
<223>  Xaa indicates a D-lysine residue in which the side chain is 
       conjugated to the substituent Z1- or Z1Z2

<400>  103

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp Xaa Xaa Xaa Xaa Xaa Xaa 
        35                  


<210>  104
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Xaa indicates an L-lysine residue in which the side chain is 
       conjugated to the substituent Z1- or Z1Z2

<400>  104

His Xaa Glu Gly Ser Phe Thr Ser Glu Xaa Ala Thr Ile Leu Asp Glu 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  105
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (17)..(17)
<223>  Xaa indicates an L-lysine residue in which the side chain is 
       conjugated to the substituent Z1- or Z1Z2

<400>  105

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Glu Gly 
1               5                   10                  15      


Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  106
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (20)..(20)
<223>  Xaa indicates an L-lysine residue in which the side chain is 
       conjugated to the substituent Z1- or Z1Z2

<400>  106

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu 
1               5                   10                  15      


Gln Ala Ala Xaa Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  107
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (20)..(20)
<223>  Xaa indicates an L-lysine residue in which the side chain is 
       conjugated to the substituent Z1- or Z1Z2

<400>  107

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu 
1               5                   10                  15      


Gln Ala Ala Xaa Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  108
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Xaa indicates an L-lysine residue in which the side chain is 
       conjugated to the substituent Z1- or Z1Z2

<400>  108

His Xaa Glu Gly Thr Phe Thr Ser Glu Xaa Ala Thr Ile Leu Asp Glu 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  109
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (17)..(17)
<223>  Xaa indicates an L-lysine residue in which the side chain is 
       conjugated to the substituent Z1- or Z1Z2

<400>  109

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Ala 
1               5                   10                  15      


Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  110
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (20)..(20)
<223>  Xaa indicates an L-lysine residue in which the side chain is 
       conjugated to the substituent Z1- or Z1Z2

<400>  110

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Ala 
1               5                   10                  15      


Lys Ala Ala Xaa Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  111
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400>  111

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Glu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  112
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400>  112

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Glu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  113
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400>  113

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Glu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  114
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400>  114

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Lys Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  115
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400>  115

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Lys Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  116
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400>  116

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Lys Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  117
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (17)..(17)
<223>  Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400>  117

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Gly 
1               5                   10                  15      


Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  118
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (17)..(17)
<223>  Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400>  118

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Gly 
1               5                   10                  15      


Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  119
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (17)..(17)
<223>  Xaa  is K([17-carboxy-heptadecanoyl]-isoGlu)

<400>  119

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Gly 
1               5                   10                  15      


Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  120
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400>  120

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  121
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400>  121

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  122
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400>  122

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  123
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400>  123

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  124
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400>  124

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  125
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400>  125

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  126
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400>  126

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Glu Ala Ala Arg Leu Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  127
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400>  127

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  128
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400>  128

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  129
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400>  129

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  130
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400>  130

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  131
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400>  131

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  132
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400>  132

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  133
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400>  133

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  134
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400>  134

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  135
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400>  135

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  136
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400>  136

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile His His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  137
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400>  137

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Tyr His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  138
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400>  138

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Leu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  139
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400>  139

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Lys His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  140
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400>  140

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Arg His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  141
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  misc
<222>  (16)..(16)
<223>  Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400>  141

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ser His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  142
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is K([Hexadecanoyl]-betaAla)

<400>  142

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Gln Gln His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  143
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is K([17-carboxy-heptadecanoyl]iso-Glu-Peg3)

<400>  143

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Tyr Gln His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  144
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is K([19-carboxy-nonadecanoyl]iso-Glu-Peg3-Peg3)

<400>  144

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Lys Gln His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  145
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is K([19-carboxy-nonadecanoyl]iso-Lys-Peg3-Peg3-Peg3)

<400>  145

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln Gln Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  146
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is K(Octadecanoyl)

<400>  146

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln Tyr Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  147
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is K(Hexadecanoyl-isoGlu)

<400>  147

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ser Thr Ile Leu Glu Xaa 
1               5                   10                  15      


Gln Ala Ser Arg Glu Phe Ile Ala Trp Leu Ile Ala Tyr Lys Ile Thr 
            20                  25                  30          


Glu 
    


<210>  148
<211>  40
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib


<220>
<221>  MISC_FEATURE
<222>  (34)..(38)
<223>  Xaa at positions 34-39 is D-Lys

<220>
<221>  MISC_FEATURE
<222>  (39)..(39)
<223>  Xaa is a D-lysine residue in which the side chain is conjugated to ([17-carboxy-Heptadecanoyl]-isoGlu)

<400>  148

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Glu 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr 
            20                  25                  30          


Asp Xaa Xaa Xaa Xaa Xaa Xaa
        35                   


<210>  149
<211>  40
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (34)..(38)
<223>  Xaa at positions 34-38 is D-Lys

<220>
<221>  MISC_FEATURE
<222>  (39)..(39)
<223>  Xaa is a D-lysine residue in which the side chain is conjugated to ([17-carboxy-Heptadecanoyl]-isoGlu)

<400>  149

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr 
            20                  25                  30          


Asp Xaa Xaa Xaa Xaa Xaa Xaa 
        35                  


<210>  150
<211>  40
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (34)..(38)
<223>  Xaa at positions 34-38 is D-Lys

<220>
<221>  MISC_FEATURE
<222>  (39)..(39)
<223>  Xaa is a D-lysine residue in which the side chain is conjugated to ([17-carboxy-Heptadecanoyl]-isoGlu)

<400>  150

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp Xaa Xaa Xaa Xaa Xaa Xaa 
        35                  


<210>  151
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu)

<400>  151

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  152
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Xaa is K([19-carboxy-nonadecanoyl]iso-Glu-Peg3-Peg3)

<400>  152
His Xaa Glu Gly Ser Phe Thr Ser Glu Xaa Ala Thr Ile Leu Asp Glu 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  153
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is K([19-carboxy-nonadecanoyl]iso-Glu-Peg3-Peg3)

<400>  153

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Lys Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  154
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (17)..(17)
<223>  Xaa is K([19-carboxy-nonadecanoyl]iso-Glu-Peg3-Peg3)

<400>  154

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Glu Gly 
1               5                   10                  15      


Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  155
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (20)..(20)
<223>  Xaa is K([19-carboxy-nonadecanoyl]iso-Glu-Peg3-Peg3)

<400>  155

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu 
1               5                   10                  15      


Gln Ala Ala Xaa Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  156
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (20)..(20)
<223>  Xaa is K([19-carboxy-nonadecanoyl]iso-Glu-Peg3-Peg3)

<400>  156

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu 
1               5                   10                  15      


Gln Ala Ala Xaa Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  157
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is K([17-Carboxy-heptadecanoyl]-isoGlu-KEK-Peg3)

<400>  157

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  158
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-Peg3)

<400>  158

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  159
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is K([17-Carboxy-heptadecanoyl]-isoGlu-KEK-Peg3)

<400>  159

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  160
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-Peg3)

<400>  160

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  161
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK)

<400>  161

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  162
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-Peg3)

<400>  162

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  163
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-Peg3)

<400>  163

His Xaa Glu Gly Ser Phe Thr Ser Glu Xaa Ala Thr Ile Leu Asp Glu 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  164
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-Peg3)

<400>  164

His Xaa Glu Gly Thr Phe Thr Ser Glu Xaa Ala Thr Ile Leu Asp Glu 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  165
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Xaa is K([19-carboxy-nonadecanoyl]iso-Glu-KEK-Peg3-Peg3)

<400>  165

His Xaa Glu Gly Ser Phe Thr Ser Glu Xaa Ala Thr Ile Leu Asp Glu 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  166
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-Peg3)

<400>  166

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  167
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-Peg3)

<400>  167

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  168
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-Peg3)

<400>  168

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  169
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-Peg3)

<400>  169

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Lys Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  170
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is K([19-carboxy-nonadecanoyl]iso-Glu-KEK-Peg3-Peg3)

<400>  170

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa 
1               5                   10                  15      


Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  171
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (17)..(17)
<223>  Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-Peg3)

<400>  171

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Glu Gly 
1               5                   10                  15      


Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  172
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (17)..(17)
<223>  Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-Peg3)

<400>  172

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Ala 
1               5                   10                  15      


Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  173
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (17)..(17)
<223>  Xaa is K([19-carboxy-nonadecanoyl]iso-Glu-KEK-Peg3-Peg3)

<400>  173

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Ala 
1               5                   10                  15      


Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  174
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (20)..(20)
<223>  Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-Peg3)

<400>  174

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu 
1               5                   10                  15      


Gln Ala Ala Xaa Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  175
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (20)..(20)
<223>  Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-Peg3)

<400>  175

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu 
1               5                   10                  15      


Gln Ala Ala Xaa Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  176
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (20)..(20)
<223>  Xaa is K([19-carboxy-nonadecanoyl]iso-Glu-KEK-Peg3-Peg3)

<400>  176

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu 
1               5                   10                  15      


Gln Ala Ala Xaa Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  177
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (20)..(20)
<223>  Xaa is K([19-carboxy-nonadecanoyl]iso-Glu-KEK-Peg3-Peg3)

<400>  177

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu 
1               5                   10                  15      


Gln Ala Ala Xaa Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  178
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  GLP-1/GLP-2 Dual agonist peptide


<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  Aib

<220>
<221>  MISC_FEATURE
<222>  (20)..(20)
<223>  Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-Peg3)

<400>  178

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Ala 
1               5                   10                  15      


Lys Ala Ala Xaa Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr 
            20                  25                  30          


Asp 
    
